Period Groups | Body weight (g) | Body Weight Gains During Treatment (g) | |||
---|---|---|---|---|---|
At OVXα | At Initial Treatmentα | At Sacrificeα | |||
Sham | 23.14 ± 1.23b | 24.57 ± 0.96c | 26.71 ± 2.51d | 2.14 ± 1.1cd | |
OVX | – | 24.29 ± 2.1 a | 29.67 ± 1.15 a | 36.59 ± 1.98a | 6.92 ± 1.8 ab |
SME 50 mg/kg | 24.37 ± 1.53 a | 28.93 ± 0.82ab | 35.71 ± 1.15ab | 6.78 ± 1.17ab | |
SME 100 mg/kg | 24.1 ± 1.62 a | 28.71 ± 0.96ab | 35.95 ± 1.98ab | 7.24 ± 0.82a | |
SME 200 mg/kg | 23.94 ± 0.95ab | 28.5 ± 0.84b | 36.1 ± 2.23a | 7.6 ± 1.94a | |
SML 50 mg/kg | 24.22 ± 1.15 a | 29.14 ± 1.11a | 35.74 ± 1.92ab | 6.6 ± 1.3b | |
SML 100 mg/kg | 24.41 ± 1.42 a | 28.59 ± 1.26ab | 36.25 ± 2.68a | 7.7 ± 2.21a | |
SML 200 mg/kg | 24.37 ± 1.27 a | 28.63 ± 1.29ab | 32.59 ± 2.11b | 3.96 ± 2.05c | |
LCa 10 ml/kg | 24.51 ± 0.85a | 27.92 ± 2.21bc | 34.93 ± 1.29ab | 7.01 ± 1.82a | |
E2 0.1 mg/kg | 24.62 ± 1.09a | 28.15 ± 1.42b | 30.21 ± 1.38c | 2.06 ± 2.13d |